Dynamic monitoring of the efficacy of T-cell immunotherapy
Chimeric antigen receptor T-cell (CAR-T) immunotherapy has become a hot research topic both domestically and internationally due to its significant therapeutic effects in treating hematological malignancies. Accurately assessing, monitoring, and managing CAR-T therapy in the complex clinical environment of CAR-T treatment presents a major challenge. Immune profiling sequencing technology can digitally evaluate and monitor the treatment process and outcomes by tracking the dynamic changes of three types of cells: tumor cells (for efficacy assessment through MRD monitoring), CAR-T cells (for monitoring CAR-T expansion and persistence), and newly generated autologous immune cells (for immune reconstitution).






